image credit: Unsplash

Biogen scraps late-stage study for Parkinson’s drug

Biogen has disclosed plans to stop a late-stage clinical trial testing one of its drugs as a potential treatment for Parkinson’s disease.

According to a Monday announcement, the decision is due to several factors, including the trial’s complexity and run time. Results weren’t expected to come in until early 2031. Another, ongoing study evaluating the drug in early Parkinson’s patients will continue, with its protocol amended to allow eligible participants from the discontinued trial to enroll.

Read More on Biopharma Dive